14 years ago
7405 views
Posted
22nd February, 2010 00h00
A new publication into the benefits of spironolactone, the active ingredient in Prilactone® manufactured by CEVA Animal Health, has supported the use of the product as part of first-line therapy for the treatment of dogs with congestive heart failure caused by mitral heart disease.
The double-blind placebo-controlled study1 involved 212 dogs on either spironolactone or a placebo, in addition to conventional therapy including an ACE inhibitor and furosemide. It revealed that over a 15 month period 25.5% of dogs either died, were euthanased or severely worsened in the placebo group compared to 10.8% in the spironolactone group. This represents a 55% reduction in the risk of cardiac morbidity-mortality and a 69% reduction in the risk of cardiac-related death or euthanasia.
Further research2 has also revealed that aldosterone antagonists, such as spironolactone, help to prevent myocardial fibrosis, a pathogenic process involved in the progression of heart failure.
Information is available by calling Fraser Broadfoot MRCVS at CEVA Animal Health on 01494 781510.
